HK1096396A1 - New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations - Google Patents

New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Info

Publication number
HK1096396A1
HK1096396A1 HK07103565.2A HK07103565A HK1096396A1 HK 1096396 A1 HK1096396 A1 HK 1096396A1 HK 07103565 A HK07103565 A HK 07103565A HK 1096396 A1 HK1096396 A1 HK 1096396A1
Authority
HK
Hong Kong
Prior art keywords
rifaximin
production
medicinal preparations
polymorphous forms
processes
Prior art date
Application number
HK07103565.2A
Other languages
English (en)
Inventor
Viscomi Giuseppe Claudio
Campana Manuela
Confortini Donatella
Barbanti Maria Miriam
Braga Dario
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34934045&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1096396(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of HK1096396A1 publication Critical patent/HK1096396A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44Compounds with an amino radical acylated by carboxylic acids, attached in position 6
    • C07D499/48Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical
    • C07D499/58Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical
    • C07D499/64Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with a carbon chain, substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, attached to the carboxamido radical substituted in alpha-position to the carboxamido radical by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK07103565.2A 2005-03-03 2007-04-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations HK1096396A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05004695.2A EP1698630B1 (en) 2005-03-03 2005-03-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Publications (1)

Publication Number Publication Date
HK1096396A1 true HK1096396A1 (en) 2007-06-01

Family

ID=34934045

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103565.2A HK1096396A1 (en) 2005-03-03 2007-04-03 New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Country Status (28)

Country Link
US (9) US8193196B2 (xx)
EP (1) EP1698630B1 (xx)
JP (2) JP5737825B2 (xx)
KR (1) KR100885755B1 (xx)
CN (1) CN1900077B (xx)
AU (1) AU2006222312B8 (xx)
BR (1) BRPI0608073A8 (xx)
CA (1) CA2594789C (xx)
DK (1) DK1698630T3 (xx)
ES (1) ES2522895T3 (xx)
HK (1) HK1096396A1 (xx)
HR (1) HRP20070433B1 (xx)
IL (1) IL184694A0 (xx)
MA (1) MA29345B1 (xx)
MD (1) MD4081G2 (xx)
ME (1) ME00272B (xx)
MX (1) MX2007010742A (xx)
NO (1) NO342197B1 (xx)
NZ (1) NZ556737A (xx)
PL (1) PL1698630T3 (xx)
PT (1) PT1698630E (xx)
RS (1) RS54570B1 (xx)
RU (1) RU2397985C2 (xx)
SI (1) SI1698630T1 (xx)
TN (1) TNSN07292A1 (xx)
UA (1) UA89809C2 (xx)
WO (1) WO2006094662A1 (xx)
ZA (1) ZA200707397B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) 2006-09-22 2014-01-21 Cipla Limited Rifaximin
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA101829C2 (uk) * 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
PL2252148T3 (pl) 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
KR20110071096A (ko) 2008-09-26 2011-06-28 아스카 세이야쿠 가부시키가이샤 기능성 소화관 장해의 예방 및/또는 치료제
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ,リミテッド 過敏性腸症候群(ibs)の治療方法
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN101836959A (zh) * 2010-05-20 2010-09-22 山东达因海洋生物制药股份有限公司 一种制备几乎无苦味利福昔明干混悬剂的方法
EP2582707A4 (en) * 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
WO2012009388A1 (en) 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
CA2825964A1 (en) * 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2013027227A1 (en) * 2011-07-20 2013-02-28 Ind-Swift Laboratories Limited Novel polymorphic form i of rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
ES2829285T3 (es) 2013-04-12 2021-05-31 Alfasigma Spa Administración de AINE y composiciones, métodos y sistemas relacionados
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
US20150103715A1 (en) * 2013-10-14 2015-04-16 Qualcomm Incorporated Downlink control format indicator
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) * 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
WO2017015152A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny
IT201700091912A1 (it) * 2017-08-08 2019-02-08 Biofer Spa Nuove pirido-imidazo rifamicine
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
AU2020355603A1 (en) 2019-09-24 2022-03-17 Bausch Health Ireland Limited Rifaximin liquid formulations
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE751182A (fr) 1969-05-30 1970-11-03 Takeda Chemical Industries Ltd Procede de fabrication d'antibiotiques
CH571064A5 (en) 1973-03-01 1975-12-31 Archifar Ind Chim Trentino Recovery of rieamycin from broths - by oxidn to an insol form
US4267274A (en) 1973-04-26 1981-05-12 Gruppo Lepetit S.P.A. Streptomyces mediterranei mutant capable of production of rifamycin B
GB1470426A (en) 1974-08-30 1977-04-14 Lepetit Spa Rifamycins
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
CA2082809C (en) * 1990-06-29 1995-10-17 Marino Nebuloni Pure crystalline form of rifapentine
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US6271001B1 (en) 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
AU4988197A (en) 1996-10-16 1998-05-11 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer antidiarrheal compo sitions
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US20030157174A1 (en) 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
KR100765683B1 (ko) 2001-05-03 2007-10-11 파르미게아 에스.피.에이 자궁경부 침습질환을 치료하기 위한 수크랄페이트 또는 그의 수크로오스 옥타술레이트
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2488011C (en) 2002-06-03 2008-02-12 Cac Corporation External preparations for treating dermatitis
CZ13908U1 (cs) 2003-10-08 2004-01-05 Cpn Spol. S R.O. Kosmetický přípravek s vysokomolekulární antioxidační složkou
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
AP2007003915A0 (en) 2004-07-16 2007-02-28 Cipla Ltd Anti-histaminic composition
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) 2006-09-22 2014-01-21 Cipla Limited Rifaximin
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
SI2011486T1 (sl) 2007-07-06 2012-10-30 Lupin Ltd Farmacevtski sestavki rifaksimina
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US8974825B2 (en) 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
JP2010259452A (ja) * 2007-08-21 2010-11-18 Konica Minolta Medical & Graphic Inc 画像診断支援装置及び画像診断支援方法
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
PL2252148T3 (pl) 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
SI2294012T1 (sl) 2008-05-07 2014-11-28 Salix Pharmaceuticals, Ltd. Dajanje ÄŤistila za ÄŤrevo in antibiotika za zdravljenje ÄŤrevesne bolezni
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2010040020A1 (en) 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
JP5276505B2 (ja) * 2009-04-06 2013-08-28 株式会社ユニバーサルエンターテインメント 遊技機
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
AU2010260089B2 (en) 2009-06-15 2015-05-14 Salix Pharmaceuticals, Inc. Modulation of systemic exposure to rifaximin
JP2013504597A (ja) 2009-09-13 2013-02-07 サリックス ファーマスーティカルズ,リミテッド 過敏性腸症候群(ibs)の治療方法
US8772242B2 (en) 2009-10-26 2014-07-08 Thomas Julius Borody Therapy for enteric infections
MX346660B (es) 2009-10-27 2017-03-28 Lupin Ltd Dispersion solida de rifaximina.
WO2011061748A1 (en) 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
US20130202654A1 (en) 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
MX2012005883A (es) 2009-11-23 2012-10-09 Cipla Ltd Composicion topica en espuma.
US8952159B2 (en) 2009-12-28 2015-02-10 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药***
WO2011103246A1 (en) 2010-02-18 2011-08-25 Salix Pharmaceuticals, Ltd. Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP6092629B2 (ja) 2010-03-10 2017-03-08 ルピン・リミテッドLupin Limited リファキシミン使用準備済懸濁液
ES2682051T3 (es) 2010-04-23 2018-09-18 The Procter & Gamble Company Composición detergente
BR112012030783A2 (pt) 2010-06-03 2015-09-29 Salix Pharmaceuticals Ltd formas de rifaximina e seus usos
EP2582707A4 (en) 2010-06-16 2014-01-08 Apotex Pharmachem Inc POLYMORPHIC FORMS OF RIFAXIMINE
WO2012009388A1 (en) 2010-07-12 2012-01-19 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
CA2825964A1 (en) 2011-02-11 2012-08-16 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
CA2834829A1 (en) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
WO2013067394A1 (en) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd Methods for treating irritable bowel syndrome (ibs) and infections
JP2015509105A (ja) 2012-01-25 2015-03-26 サリックス ファーマスーティカルズ,リミテッド リファキシミン誘導体及びその使用
JP2013184902A (ja) 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
ES2829285T3 (es) 2013-04-12 2021-05-31 Alfasigma Spa Administración de AINE y composiciones, métodos y sistemas relacionados
WO2014186675A1 (en) 2013-05-17 2014-11-20 Salix Pharmaceuticals, Inc. Methods of using rifaximin in position emission tomography (pet) scans
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ITMI20131307A1 (it) 2013-08-02 2015-02-02 A M S A Anonima Materie Sint & Affini S P A Processo per la preparazione di refaximina k
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015159275A2 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
WO2016063289A2 (en) 2014-10-22 2016-04-28 Strides Arcolab Limited Pharmaceutical tablet compositions comprising rifaximin
WO2017021975A1 (en) 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3373914B2 (en) 2016-03-24 2022-06-01 Sandoz AG Storage stable composition comprising rifaximin alpha
US10576065B2 (en) 2016-03-24 2020-03-03 Sandoz Ag Pharmaceutical composition containing rifaximin alpha and delta
US9988398B2 (en) 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
WO2018158646A1 (en) 2017-03-02 2018-09-07 Granules India Limited Rifaximin crystalline form
WO2018178777A1 (en) 2017-03-31 2018-10-04 Granules India Limited Process for the preparation of rifaximin crystalline form
CA3013161C (en) 2017-04-26 2020-03-24 Sandoz Ag Oral dosage form comprising rifaximin in form beta
PL3645539T3 (pl) 2017-06-26 2021-10-25 Biofer S.P.A. Pochodne pirydoimidazoryfamycyny jako środek przeciwbakteryjny

Also Published As

Publication number Publication date
US20160362419A1 (en) 2016-12-15
RS54570B1 (en) 2016-06-30
PT1698630E (pt) 2014-09-15
US20220119403A1 (en) 2022-04-21
ES2522895T3 (es) 2014-11-19
NO342197B1 (no) 2018-04-16
RU2397985C2 (ru) 2010-08-27
NO20074988L (no) 2007-11-30
MD20070265A (en) 2008-05-31
AU2006222312B2 (en) 2011-11-03
UA89809C2 (uk) 2010-03-10
PL1698630T3 (pl) 2014-12-31
US8193196B2 (en) 2012-06-05
KR20060096242A (ko) 2006-09-11
US8518949B2 (en) 2013-08-27
JP5737825B2 (ja) 2015-06-17
HRP20070433B1 (hr) 2015-02-27
CN1900077A (zh) 2007-01-24
NZ556737A (en) 2011-11-25
US8741904B2 (en) 2014-06-03
MD4081G2 (ro) 2011-07-31
KR100885755B1 (ko) 2009-02-26
JP2008531623A (ja) 2008-08-14
US20200277301A1 (en) 2020-09-03
US20200002350A1 (en) 2020-01-02
US10703763B2 (en) 2020-07-07
RU2007136430A (ru) 2009-04-10
ZA200707397B (en) 2009-03-25
ME00272B (me) 2011-05-10
US20090130201A1 (en) 2009-05-21
MA29345B1 (fr) 2008-03-03
BRPI0608073A2 (pt) 2009-11-03
EP1698630B1 (en) 2014-09-03
WO2006094662A1 (en) 2006-09-14
US20120245355A1 (en) 2012-09-27
IL184694A0 (en) 2007-12-03
EP1698630A1 (en) 2006-09-06
SI1698630T1 (sl) 2015-01-30
AU2006222312B8 (en) 2011-11-17
CA2594789A1 (en) 2006-09-14
CA2594789C (en) 2010-09-14
AU2006222312A1 (en) 2006-09-14
US20150073007A1 (en) 2015-03-12
JP2013216710A (ja) 2013-10-24
US20130310410A1 (en) 2013-11-21
TNSN07292A1 (en) 2008-12-31
HRP20070433A2 (en) 2007-11-30
CN1900077B (zh) 2012-04-11
US20180291032A1 (en) 2018-10-11
RS20070364A (xx) 2009-01-22
MX2007010742A (es) 2007-09-12
DK1698630T3 (da) 2014-12-08
US9271968B2 (en) 2016-03-01
BRPI0608073A8 (pt) 2017-12-26
MD4081F2 (en) 2010-12-31
MEP34408A (en) 2011-02-10
EP1698630A8 (en) 2006-10-25

Similar Documents

Publication Publication Date Title
HK1096396A1 (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
TNSN06069A1 (en) Polymorphous forms of rifaximin as antibiotics
MX2009007730A (es) Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.
WO2008006979A3 (fr) Procede de preparation de composes diaminophenothiazinium.
EP1619199A4 (en) GLYCOLIPIDE DERIVATIVES, METHOD OF MANUFACTURING THEREOF, INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS AND PRODUCTION PROCESSES FOR THE INTERMEDIATE PRODUCTS
AU2003298218A1 (en) Composition for controlled tempering by means of phase change, production and use thereof
MY144578A (en) New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
EP1405857A4 (en) PROCESS FOR THE PRODUCTION OF OXAZOLINE-SACCHARIDE DERIVATIVES
ZA200706067B (en) Production process for NSAID-containing lozenges, their compositions, their medicinal use
EP1686105B8 (de) Verfahren zum Herstellen feuerfester Feuerleichtsteine
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir
ZA200809206B (en) Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled by precipitation and pharmaceutical formulations containing same
GB2402038B (en) Process for the production of confectionery products
WO2008056377A3 (en) Polymorphic forms of rimonabant
DE602006003956D1 (en) Novel polysubstituted 1,1-pyridinylaminocyclopropanamine derivatives, processes for their preparation and pharmaceutical composition containing them
WO2006111251A3 (en) Hydro-alcoholic extract of butea frondosa flowers, a process for its preparation, pharmaceutical compositions containing it and its use for the treatment of ulcer
WO2007034183A3 (en) Process for the preparation of 4-aminopyrazole derivatives
FR2853651B1 (fr) Procede de preparation du 4,10 beta-diacetoxy-2 alpha- benzoyloxy-5 beta, 20-epoxy-1, 13 alpha-dihydroxy-9-oxo-19- norcyclopropa[g]tax-11-ene
HK1089750A1 (en) A method for the preparation of crystalline dexloxiglumide
AU2003903332A0 (en) Process for the production of plant ingredients
EP1594877A4 (en) PROCESS FOR PRODUCING ANDROSTANE-2-OXA-3-ONE DERIVATIVES
AP1617A (en) Process for preparation of raw matooke (banana) flour
IL170747A0 (en) Process for the production of imidazopyridin-8-one derivatives